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Background/Aims: Transarterial chemoembolization (TACE) improves the survival of patients with unresectable hepatocellular 
carcinoma (HCC) and has been recommended as a first-line therapy for nonsurgical patients with large or multifocal HCC. The 
long-term outcome of HCC patients receiving TACE prior to hepatic resection is uncertain. Methods: Between January 1997 and 
December 2007, 1,530 patients underwent hepatic resection for HCC at our center. Thirty-two patients received 1~12 sessions 
of TACE followed by surgical resection (TACE-surgery group). Their overall and recurrence-free survival rates were compared 
with those of 64 age- and sex-matched controls who underwent surgery only (surgery group). Overall and recurrence-free 
survival rates were analyzed. Results: The 1-, 2-, and 5-year overall survival rates did not differ significantly between the 
TACE-surgery group and the surgery group (78%, 60%, and 26%, respectively, vs. 97%, 83%, and 45%, respectively; P=0.11); 
however, the 1-, 2-, and 5-year recurrence-free survival rates were significantly lower in the TACE-surgery group than in the 
surgery group (58%, 36%, and 7%, respectively, vs. 77%, 58%, and 32%, respectively; P=0.01). The distribution of recurrence 
sites in the TACE-surgery group were intrahepatic in 85.7% and extrahepatic in 14.3%, and did not differ from those in the surgery 
group (91.4% and 8.6%, respectively; P=0.66). Conclusions: HCC patients who underwent TACE before resection appear to 
have overall survival rates that are comparable to those without preoperative therapy, although recurrence rates appear to be 
higher in patients with TACE. (Korean J Hepatol 2010;16:383-388)
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common 
cancer and the third most common cause of cancer-related death 
in the world.
1,2 For selected patients with HCC, hepatic resection 
is one of the most reliable curative treatments, showing a 5-year 
survival rate of 50% or higher.
3 However, because of advanced 
stage of HCC and/or inadequate functional hepatic reserve, only 
9~30% of newly diagnosed patients are candidates for surgical 
resection.
3-7
Transarterial chemoembolization (TACE) involves the injection 
of lipiodol (iodized poppyseed oil) and a chemotherapeutic agent 
into the hepatic artery supplying the tumor, followed by 
embolization with gelatin or gelfoam particles. Recent systematic 
reviews have demonstrated that TACE improves survival of 
patients with unresectable HCC and the procedure may become 
one of the standard treatments for HCC.
8-10  TACE has been 
recommended as first-line therapy for nonsurgical patients with 
large or multifocal HCC.
11
In the past, lipiodol computed tomography (CT) taken after 
TACE had been one of the most useful and frequently used tools 
for diagnosis and precise staging of HCC before surgery. Since 
the introduction of advanced imaging modalities such as 
dynamic CT and magnetic resonance image (MRI) with 384  The Korean Journal of Hepatology Vol. 16. No. 4, December 2010
hepatocyte-specific contrast media, diagnostic role of TACE is 
gradually decreasing. However, TACE is still necessary prior to 
surgical resection in a portion of HCC patients after performing 
all available imaging, tumor markers, and even biopsy; for 
accurate diagnosis and staging of intrahepatic disease, reduction 
in the size of the tumor to increase resectablility, or palliative 
control of HCC when surgery is temporarily impossible.
12-14  
However, long term prognosis of hepatic resection in HCC 
patients with preoperative TACE remains uncertain.
14-19 
Hence, we compared the outcome of HCC patients who 
underwent surgical resection following various sessions of 
preoperative TACE with that of patients who underwent surgery 
without any preoperative treatment, focusing on overall and 
recurrence-free survival and patterns of recurrence.
METHODS
Patients, treatments, and follow up
From January 1997 to December 2007, 1,530 patients underwent 
hepatic resection for HCC at our center. Of these, 32 patients 
underwent one or more sessions of TACE and no other treatment 
for HCC before surgical resection (TACE-surgery group). 
Among patients who did not receive any kind of treatment for 
their HCC prior to surgery, 64 age- and sex-matched patients 
were chosen as controls using a random number table (surgery 
group). Patients who underwent other forms of treatment such as 
radiofrequency ablation before surgery or those who received 
liver transplantation were excluded.
The diagnosis of HCC was based on histological criteria 
and/or imaging techniques and alpha-fetoprotein (AFP) levels, 
as proposed by the Korean Liver Cancer Study Group and the 
National Cancer Center.
20,21 HCC was initially diagnosed for a 
combination of AFP > 400 ng/mL and a positive arterial image, 
or AFP < 400 ng/mL and positive arterial images from at least 
two modalities. All tumors were consequently confirmed as 
HCC by histological examination of surgical specimens. Tumors 
were staged according to the modified UICC classification 
system by Korean Liver Cancer Study Group.
21
Patients in the TACE-surgery group received 1-12 sessions of 
TACE [2.6±2.1, mean±standard deviation (SD)] prior to resection. 
Main reasons for preoperative TACE were confirmation of the 
diagnosis and staging of liver lesions (n=18, 46.3%), down- 
staging of tumors (n=9, 28.1%), and palliative control of HCC 
when surgery is temporarily impossible due to patients’ refusal 
(n=4, 12.5%) or recent traffic accident (n=1, 3.1%). Surgery was 
done 102.9±130.7 days (mean±SD) after last TACE in TACE- 
surgery group. Interval from the diagnosis of HCC to operation 
was 322.7±403.6 days (mean±SD) in TACE-surgery group and 
18.5±12.4 days (mean±SD) in surgery group (P<0.001). 
None of the patients received post-operative adjuvant treatment. 
The routine post-operative follow-up protocol included biochemical 
liver function tests, serum AFP concentrations, and triphasic 
dynamic CT scan performed every 3 months during the first 2 
years after surgery, and every 4~6 months thereafter. 
TACE method
A vascular catheter was inserted through the femoral artery, 
and hepatic angiography was performed. After assessing the 
hepatic vascular anatomy, TACE was performed through lobar or 
segmental hepatic arteries. In all patients, TACE was performed 
with a mixture of iodized oil (Lipiodol; Guerbet, Aulnay-sous-Bois, 
France) and doxorubicin hydrochloride (Adriamycin; Kyowa 
Hakko Kogyo, Tokyo, Japan) at a dose of 3 mg doxorubicin 
hydrochloride and 1 cc iodized oil per 1 cm tumor diameter. 
Gelfoam powder (Upjohn, Kalamazoo, MI, U.S.A) was used for 
particle embolization. The injection was continued until stasis 
was identified in the feeding artery. 
Analysis of outcome
Baseline characteristics of patients and tumors were evaluated 
in the TACE-surgery group and surgery group. Overall and 
recurrence-free survival rates and sites of recurrence after 
resection were compared between the two groups.
Statistical analysis
Categorical variables were summarized as frequency and 
percentage while continuous variables were presented as 
mean±SD. In order to compare TACE-surgery group and surgery 
only group, the Fisher’s exact tests or chi-square tests were 
performed for categorical variables and the Mann-Whitney tests 
were used for continuous variables. Overall and disease free 
survival curves were estimated using a Kaplan-Meier method. 
These curves were compared between TACE-surgery group and 
surgery only group by a log-rank test. All data analyses were 
performed using statistical package SAS Enterprise Guide 3.0 
(SAS Institute Inc., Cary, NC, USA). P<0.05 was considered 
statistically significant.Ja Young Kang, et al. Preoperative TACE and resection for HCC  385
Table 1. Baseline characteristics of patients in the preoperative transarterial chemoembolization (TACE)-surgery and surgery groups
Variables TACE-surgery group (n=32) Surgery group (n=64) P-value
Age (yr) 52.4±9.8 54.0±10.8 0.47
Male, n (%) 25 (78.1%) 51 (79.7%) 0.86
HBsAg (+) 27 (84.4%) 50 (78.1%) 0.59
Ant-HCV (+) 2 (6.3%) 8 (12.5%) 0.49
Child-Pugh class A/B 30 (93.8%)/2 (6.2%) 64 (100%)/0 (0.0%) 0.11
Albumin (g/dL) 4.04±0.40 4.03±0.38 0.99
Bilirubin (mg/dL) 0.68±0.43 0.69±0.26 0.22
Prothrombin time (sec) 14.09±1.31 14.23±0.83 0.17
AFP (ng/mL) 9,584.4±26,238.5 5,100.9±2,4773.9 0.12
Results are expressed as mean±SD or n (%).
P-value was obtained by the Mann-Whitney test or Fisher’s exact test.
TACE, transarterial chemoembolization; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; AFP, alpha fetoprotein.
Table 2. Baseline characteristics of tumors in the TACE-surgery and surgery groups
Variables TACE-surgery group (n=32) Surgery group (n=64) P-value
Number 1.44±0.62 (1~3) 1.19±0.59 (1~4) 0.06
Size (cm) 4.28±2.51 (1.0~8.8) 4.58±3.22 (1.0~15.5) 0.92
Stage
* 0.31
  I 3 (9.4%)  8 (12.5%)
  II 19 (59.4%) 46 (71.9%)
  III  8 (25.0%)  9 (14.1%)
  IVa 2 (6.2%) 1 (1.5%)
Results are expressed as mean±SD (range) or n (%).
P-value was obtained by the Mann-Whitney test or chi-square test.
* Modified UICC, Korean Liver Cancer Study Group.
TACE, transarterial chemoembolization.
RESULTS
Baseline characteristics of the patients and tumors
The TACE-surgery group consisted of 25 males (78.1%) and 7 
females (21.9%) aged 52.4±9.8 years. Twenty-seven patients 
(84.4%) were HBV-positive and 30 patients (93.8%) had liver 
function corresponding with Child-Pugh class A. The serum 
AFP level was 9,584.4±26,238.5 ng/mL. All these characteristic 
of the TACE-surgery group were similar to those of the surgery 
group (Table 1).
As for tumor characteristics, the numbers of tumors in the 
TACE-surgery group were one in 20 patients (62.5%), two in 10 
patients (31.3%), and three or more in 2 patients (6.2%). The 
tumor size was 4.3±2.5 cm. Modified UICC stage in the 
TACE-surgery group were as follows; stage I in 3 patients 
(9.4%), II in 19 patients (59.4%), III in 8 patients (25.0%) and 
IVa in 2 patients (6.2%). All these tumor characteristics were not 
significantly different between the TACE-surgery group and the 
surgery group (Table 2). 
Outcome after resection in TACE-surgery group 
and surgery group
During a follow-up period of 3.2~123 months (37.3±7.7), 
overall and recurrence-free survival rates after resection were 
compared between the two groups. The 1-, 2-, and 5-year overall 
survival rates of the TACE-surgery group were not significantly 
different from those of the surgery group (78%, 60%, and 26% 
vs. 97%, 83%, and 45%, P=0.11; Fig. 1). Subgroup analysis 
according to tumor stage showed that the 1-, 2-, and 5-year 
overall survival rates of the TACE-surgery group were not 
significantly different from those of the surgery group (78%, 
60%, and 37% vs. 98%, 83%, and 47%, P=0.35 in stage I-II; 
70%, 54%, and 0% vs. 84%, 75%, and 17%, P=0.36 in stage 
III-IVa). However, the 1-, 2-, and 5-year recurrence-free survival 386  The Korean Journal of Hepatology Vol. 16. No. 4, December 2010
Table 3. Sites of recurrence in the TACE-surgery and surgery groups
TACE-surgery group (n=32) Surgery group (n=64) P-value
*
Intrahepatic 18 (85.7%) 32 (91.4%) 0.60
Extrahepatic  3 (14.3%)   3 (8.6%)
Results are expressed as n (%).
* Fisher’s exact test.
TACE, transarterial chemoembolization.
Figure 1. Overall survival rates after surgery in HCC patients 
with or without preoperative TACE. The 1-, 2-, and 5-year 
overall survival rates did not differ between the TACE-surgery 
group and the surgery group (78%, 60%, and 26%, respectively, 
vs. 97%, 83%, and 45%, respectively; P=0.11).
Figure 2. Recurrence-free survival rates after surgery in HCC 
patients with or without preoperative TACE. The 1-, 2-, and 
5-year recurrence-free survival rates in the TACE-surgery group 
were 58%, 36%, and 7%, respectively, and were significantly 
lower than those in the surgery group (77%, 58%, and 32%, 
respectively;  P=0.01).
Figure 3. Cumulative recurrence rate after surgery in HCC patients
with or without preoperative TACE. The 1-, 2-, and 5-year 
cumulative recurrence rates in the TACE-surgery group were 
48%, 66%, and 77%, respectively, and were significantly higher 
than those in the surgery group (29%, 46%, and 55%, respectively;
P=0.04).
rates of the TACE-surgery group were significantly lower than 
those of the surgery group (58%, 36%, and 7% vs. 77%, 58%, 
and 32%, respectively, P=0.01; Fig. 2). Hence, the 1-, 2-, and 
5-year cumulative recurrence rates in the TACE-surgery group 
were 48%, 66%, and 77%, respectively, significantly higher than 
those in the surgery group (29%, 46% and 55%, respectively; 
P=0.04; Fig. 3). Distribution of recurrence sites in the TACE- 
surgery group were intrahepatic in 85.7% and extrahepatic in 
14.3%, similar to those of the surgery group (91.4% and 8.6%, 
respectively; P=0.66; Table 3).
DISCUSSION
Although preoperative TACE still forms a part of current clinical 
practice for HCC, long term outcome after surgical resection in 
those patients remains controversial. Whereas several previous 
reports have shown that preoperative TACE is effective in 
reducing the incidence of postoperative recurrence and prolonging 
survival,
14-16 other studies have failed to show a positive effect of 
preoperative TACE.
17-19,22-26 These contradictory findings come 
from differences in study design, patient characteristics, stage of 
HCC, method and number of sessions of TACE, surgical technique, 
peri- and post-operative care and so on.
In this study, we investigated the influence of preoperative 
TACE in patients undergoing liver resection for HCC who were 
enrolled over a recent 10-year period in a single center so that the Ja Young Kang, et al. Preoperative TACE and resection for HCC  387
confounding effects of different TACE methods, surgical protocols, 
and post-operative management could be minimized. Sixty-four 
age- and sex-matched patients were randomly chosen as controls 
from patients who did not receive any kind of treatment for their 
HCC prior to surgery during the same time period. Our results 
suggest that HCC patients who underwent TACE before 
resection had overall survival rates comparable to those without 
pre-operative therapy, but recurrence rates were higher in 
patients who received preoperative TACE. In addition, preoperative 
TACE does not appear to promote extrahepatic tumor recurrence. 
In our HCC patients with preoperative TACE, overall survival 
after resection was comparable to the control group without any 
treatment prior to surgery. A previous retrospective analysis of 
the outcomes of 120 patients with HCC who underwent hepatectomy 
with or without preoperative TACE reported cumulative 1-, 3-, 
and 5-year survival rates of 87%, 50%, and 32%, respectively, 
for all patients, with no significant differences between patients 
with or without preoperative TACE.
15 Another retrospective 
study investigating the role of preoperative TACE for resectable 
HCC demonstrated that, in a TACE subgroup with tumor stage 
III-IV, preoperative TACE was supposed to reduce tumor 
recurrence and confer a survival advantage after surgery.
16 
Induction of tumor down-staging or complete necrosis by TACE 
was suggested to be associated with improved disease free 
survival.
14 On the contrary, randomized prospective studies with 
results against the benefits of preoperative TACE were performed 
mostly in patients with initially resectable HCC.
17-19 Poor 
outcome after resection in the TACE group was reported in 
patients without cirrhosis or those with stage I-II tumors.
19 
Longer operation time and/or technical difficulties during surgery, 
increased liver failure and gastrointestinal bleeding, and 
increased extrahepatic metastasis were shown to be associated 
with poor outcome after resection in patients with preoperative 
TACE.
18,22,23
Our study demonstrated that recurrence-free survival rates in 
the TACE-surgery group were significantly lower than those in 
the surgery group. While improved tumor-free survival was 
demonstrated in patients with preoperative TACE for HCC larger 
than 8 cm
15 and with advanced stage in one study,
16 most other 
studies have reported similar or lower disease-free survival rates 
in patients receiving preoperative TACE.
17-19,22 Especially, 
increased rate of recurrence, including extrahepatic metastasis, 
was reported in patients with initial resectable HCC
22 or stage I-II 
HCC
19 who received preoperative TACE. It has been suggested 
that TACE-induced necrosis might result in hematogenous 
dissemination from the primary tumor.
24 The higher incidence of 
pulmonary metastasis following TACE in patients with HCC has 
been reported; however, the subjects who developed lung 
metastasis in that series were followed for a longer period than 
those without metastasis.
25 Notably, a report suggested that 
preoperative TACE reduced the dissemination of tumor cells in 
the circulating blood during surgery.
26  Our study also shows 
similar risk for extrahepatic recurrence in the TACE-surgery 
group and the surgery group. 
Our data has weak points as a retrospective small-sized study. 
First, since surgery was done 322.7±403.6 days after initial 
diagnosis of HCC in the TACE-surgery group, HCC with 
aggressive tumor biology would be excluded during follow up 
with TACE and enrolled in this study. However, it is also possible 
that excellent responders to TACE (HCC with favorable tumor 
biology) were excluded. Second, while the TACE-surgery group 
and the surgery group shows no significant difference in all 
baseline characteristics, this similarity might come from small 
size of this study. For example, a proportion of patients with 
stage III and IVa HCC in the TACE-surgery group was higher 
than that in the surgery group (31.2% vs. 15.6%), although the 
difference did not reach clinical significance. However, subgroup 
analysis showed overall survival rates were not significantly 
different between two groups. In addition, whereas the 1-, 2-, and 
5-year overall survival rates of the TACE-surgery group were not 
significantly different from those of the surgery group (78%, 
60%, and 26% vs. 97%, 83%, and 45% respectively; P=0.11), 
statistically significant difference might be demonstrated if large 
number of patients were included in the analysis. 
In conclusion, our results suggest that HCC patients who 
underwent TACE before resection could have overall survival 
rates comparable to those without pre-operative therapy, although 
recurrence rates would be higher in patients with preoperative 
TACE. However, further large-scaled studies are warranted to 
clarify the effect of preoperative TACE on the outcome of 
patients with HCC after surgical resection.
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